Home Cancer MaxCyte Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

MaxCyte Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

135
0
Malignant Mesothelioma,

MaxCyte was formed in 1999. It specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes. Publicly traded under symbol MXCT, MaxCyte  is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top 10 global biopharmaceutical companies, and has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

Current Trial

The trial is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with recurrence after prior chemotherapy. The sponsor seeks 15 participants with an estimated completion date 2020.  Key participating research sites include the National Cancer Institute and Washington University St. Louis.

What makes MCY-M11 different from previous trials with CAR therapies is that the altered T-cells will not be given intravenously. Patients with peritoneal mesothelioma will have their T-cells injected directly into the abdominal cavity. MaxCyte is also using a new type of system for altering T-cells that is faster, allowing for quicker turnaround times in treating patients.

Lead Research/Investigator

Premal Thaker, MD

Christina Annunziata, MD, PhD

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.